- Home
- JANX vs CVAC Comparison
JANX vs CVAC Comparison
Compare JANX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CVAC
- Stock Information
- Founded
- JANX 2017
- CVAC 2000
- Country
- JANX United States
- CVAC Germany
- Employees
- JANX N/A
- CVAC N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- CVAC Health Care
- Exchange
- JANX Nasdaq
- CVAC Nasdaq
- Market Cap
- JANX 1.4B
- CVAC 1.2B
- IPO Year
- JANX 2021
- CVAC 2020
- Fundamental
- Price
- JANX $23.98
- CVAC $5.39
- Analyst Decision
- JANX Strong Buy
- CVAC Hold
- Analyst Count
- JANX 9
- CVAC 3
- Target Price
- JANX $85.00
- CVAC $6.83
- AVG Volume (30 Days)
- JANX 745.4K
- CVAC 619.8K
- Earning Date
- JANX 08-07-2025
- CVAC 08-15-2025
- Dividend Yield
- JANX N/A
- CVAC N/A
- EPS Growth
- JANX N/A
- CVAC N/A
- EPS
- JANX N/A
- CVAC 1.01
- Revenue
- JANX $439,000.00
- CVAC $599,540,810.00
- Revenue This Year
- JANX N/A
- CVAC N/A
- Revenue Next Year
- JANX $591.60
- CVAC $24.04
- P/E Ratio
- JANX N/A
- CVAC $5.37
- Revenue Growth
- JANX N/A
- CVAC 675.15
- 52 Week Low
- JANX $21.97
- CVAC $2.37
- 52 Week High
- JANX $71.71
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- JANX 49.92
- CVAC 49.09
- Support Level
- JANX $22.41
- CVAC $5.33
- Resistance Level
- JANX $24.00
- CVAC $5.48
- Average True Range (ATR)
- JANX 1.10
- CVAC 0.04
- MACD
- JANX 0.01
- CVAC -0.01
- Stochastic Oscillator
- JANX 42.20
- CVAC 38.89
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.